Jonathan L Torres

List of Publications by Year in descending order

50 papers	5,900 citations	186265 28 h-index	265206 42 g-index
71 all docs	71 docs citations	71 times ranked	9546 citing authors

#	Article	IF	Citations
1	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science, 2020, 369, 643-650.	12.6	1,104
2	SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell, 2020, 183, 1043-1057.e15.	28.9	860
3	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell, 2015, 163, 1702-1715.	28.9	341
4	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science, 2020, 370, 1089-1094.	12.6	290
5	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nature Communications, 2021, 12, 2938.	12.8	219
6	Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Nature, 2017, 547, 360-363.	27.8	217
7	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell Reports, 2016, 16, 2327-2338.	6.4	216
8	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity, 2020, 53, 1272-1280.e5.	14.3	185
9	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell, 2021, 184, 1821-1835.e16.	28.9	180
10	A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science, 2019, 366, .	12.6	172
11	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. Cell Reports, 2017, 20, 1805-1817.	6.4	171
12	Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature, 2017, 548, 108-111.	27.8	154
13	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell Reports, 2020, 33, 108274.	6.4	152
14	Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10438-E10445.	7.1	116
15	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications, 2019, 10, 2355.	12.8	116
16	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. Immunity, 2019, 51, 915-929.e7.	14.3	111
17	Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer. PLoS Pathogens, 2015, 11, e1004767.	4.7	100
18	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Reports, 2021, 36, 109353.	6.4	95

#	Article	IF	Citations
19	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj5413.	12.4	79
20	Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Science Advances, 2018, 4, eaau8529.	10.3	70
21	Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. PLoS Pathogens, 2019, 15, e1007920.	4.7	61
22	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. PLoS Pathogens, 2020, 16, e1008753.	4.7	61
23	HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies. Cell Reports, 2020, 31, 107583.	6.4	60
24	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. Journal of Virology, 2017, 91, .	3.4	57
25	Visualization of the HIV-1 Env glycan shield across scales. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28014-28025.	7.1	57
26	Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design. Cell Reports, 2018, 23, 3249-3261.	6.4	52
27	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. Cell Host and Microbe, 2019, 25, 873-883.e5.	11.0	42
28	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology, 2022, 23, 960-970.	14.5	39
29	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. Npj Vaccines, 2021, 6, 24.	6.0	33
30	Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. Scientific Reports, 2017, 7, 8390.	3.3	31
31	Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. Science Advances, 2020, 6, eaba0468.	10.3	31
32	Structure and mechanism of monoclonal antibody binding to theÂjunctional epitope of Plasmodium falciparumÂcircumsporozoite protein. PLoS Pathogens, 2020, 16, e1008373.	4.7	30
33	Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein. Journal of Molecular Biology, 2020, 432, 1048-1063.	4.2	28
34	Structural mapping of antibody landscapes to human betacoronavirus spike proteins. Science Advances, 2022, 8, eabn2911.	10.3	28
35	Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. Frontiers in Immunology, 2018, 9, 1116.	4.8	27
36	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120976119.	7.1	27

#	Article	IF	Citations
37	SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. SSRN Electronic Journal, 0, , .	0.4	13
38	One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. Emerging Microbes and Infections, 2021, 10, 2016-2029.	6.5	12
39	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Journal of Virology, 2020, 94, .	3.4	11
40	A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathogens, 2022, 18, e1010465.	4.7	8
41	Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. SSRN Electronic Journal, 0, , .	0.4	7
42	A Strain-Specific Inhibitor of Receptor-Bound HIV-1 Targets a Pocket near the Fusion Peptide. Cell Reports, 2020, 33, 108428.	6.4	5
43	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. Cell Reports, 2021, 37, 109922.	6.4	5
44	SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers. Journal of Virology, 2019, 94, .	3.4	4
45	Algal-Produced Immunotoxins. Forum on Immunopathological Diseases and Therapeutics, 2013, 4, 241-254.	0.1	0
46	A Strain-Specific Inhibitor of Receptor-Bound HIV-1 Targets a Pocket Near the Fusion Peptide and Offers a Template for Drug Design. SSRN Electronic Journal, 0, , .	0.4	0
47	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
48	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
49	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
50	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0